Loading clinical trials...
Loading clinical trials...
An Open-label, Multi-center Extension Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Crohn's Disease or Moderate to Severe Ulcerative Colitis
Conditions
Interventions
Deucravacitinib
Locations
43
United States
Local Institution - 0036
Shreveport, Louisiana, United States
Local Institution - 0002
Wyoming, Michigan, United States
Local Institution - 0037
Jackson, Mississippi, United States
Local Institution - 0041
Cleveland, Ohio, United States
Local Institution - 0038
Pittsburgh, Pennsylvania, United States
Local Institution - 0066
Charleston, South Carolina, United States
Start Date
May 7, 2021
Primary Completion Date
August 29, 2023
Completion Date
August 29, 2023
Last Updated
September 24, 2024
NCT07550673
NCT05739864
NCT04338204
NCT07271069
NCT06975722
NCT07185009
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions